Heart shock secondary to the use of clozapine
1 Internist, Universidad Metropolitana de Barranquilla, Colombia.
2 General Physician, Universidad de Sucre, Colombia.
3 General Physician, Universidad Del Sinú, Montería, Colombia.
4 General Physician, Fundación Universitaria Juan N. Corpas, Bogotá, Colombia.
5 General Physician, Universidad Autónoma de Bucaramanga, Colombia.
6 General Physician, Universidad de Boyacá, Colombia.
Review Article
World Journal of Advanced Research and Reviews, 2022, 13(03), 104–108
Article DOI: 10.30574/wjarr.2022.13.3.0211
Publication history:
Received on 01 February 2022; revised on 03 March 2022; accepted on 05 March 2022
Abstract:
Clozapine is an exceptionally effective antipsychotic and is approved only for use in refractory schizophrenia due to its adverse effects, including neutropenia, agranulocytosis, seizures, metabolic syndrome, and myocarditis. Cardiogenic shock represents a pathophysiological state where the heart is unable to maintain effective cardiac output (CO) in relation to the metabolic demands of the body, when it is derived from the use of clozapine it is an indirect complication, which occurs secondary to myocarditis due to hypersensitivity to said drug or also other myocardial conditions, myocarditis is an acute inflammatory disorder whose etiology is associated with an infectious process or mediated by an immune response either by drugs or toxins.
Keywords:
Clozapine; Cardiogenic Shock; Myocarditis; Drug
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0